Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Exact Therapeutics ASFRA:56F +3.70%21 EV-to-EBITDA is -0.78 as of Aug. 11, 2026. GuruFocus rates FRA:56F with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 402 Biotechnology companies, Exact Therapeutics AS ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Exact Therapeutics AS's enterprise value is €5.52 Mil.
Exact Therapeutics AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.12 Mil. Therefore, Exact Therapeutics AS's EV-to-EBITDA for today is -0.78.
The historical rank and industry rank for Exact Therapeutics AS's EV-to-EBITDA or its related term are showing as below:
FRA:56F'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.73 Med: 0 Max: 0
Current: -0.73
FRA:56F's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs FRA:56F: -0.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Exact Therapeutics AS (FRA:56F) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exact Therapeutics AS's PE Ratio (TTM) for today is calculated as:
Exact Therapeutics AS's share price for today is €0.028.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.117.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Exact Therapeutics AS EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Exact Therapeutics AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:56F vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Exact Therapeutics AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Therapeutics AS EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Exact Therapeutics AS's EV-to-EBITDA falls into.
Exact Therapeutics AS's current Enterprise Value is €5.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Therapeutics AS (FRA:56F) has a EV-to-EBITDA of -0.78 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Exact Therapeutics AS. According to the industry distribution chart, Exact Therapeutics AS ranks #999999 out of 402 companies in the Biotechnology industry.
Is Exact Therapeutics AS's EV-to-EBITDA too high?
Exact Therapeutics AS's current EV-to-EBITDA is -0.78. Based on the distribution chart, Exact Therapeutics AS ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Exact Therapeutics AS has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Exact Therapeutics AS ranks #999999 out of 402 companies for EV-to-EBITDA. This places Exact Therapeutics AS in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Exact Therapeutics AS. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exact Therapeutics AS's current EV-to-EBITDA is -0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current EV-to-EBITDA of -0.78. The current EV-to-EBITDA is -0.78. Exact Therapeutics AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current EV-to-EBITDA is -0.78 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
21GF Score
Get the complete analysis for FRA:56F
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:56F has been successfully added to your 
